Epitopea has appointed Dr. Lisa Butterfield to its Scientific Advisory Board, enhancing its expertise in cancer immunotherapy as it advances its RNA-based therapies for hard-to-treat solid tumors. Dr. Butterfield, a prominent figure in immuno-oncology, brings extensive experience in cancer vaccine development, immune profiling, biomarker discovery, and cell therapies. Her previous roles include leadership positions at Merck and the Parker Institute for Cancer Immunotherapy, along with significant academic contributions at institutions like the University of Pittsburgh.

The significance of Dr. Butterfield’s appointment lies in her ability to steer Epitopea’s innovative approach to cancer immunotherapy, particularly through its lead candidate, CryptiVaxMC-1001, targeting high-grade serous ovarian cancer. This therapeutic vaccine is designed to elicit targeted immune responses using a selection of tumor-specific antigens derived from the CryptigenMC class, identified through the company’s proprietary CryptoMapMC platform. This approach addresses a critical unmet need for effective treatments in advanced cancer patients, who often have limited durable options beyond biomarker-selected populations.

The takeaway from this development is the potential shift in therapeutic paradigms for solid tumors, as Epitopea aims to deliver broadly applicable and selective RNA-based immunotherapies. Dr. Butterfield’s involvement may accelerate the translation of their findings into clinical applications, ultimately impacting drug development timelines and enhancing treatment accessibility for patients with challenging malignancies. As the company progresses towards clinical phases, the integration of her expertise could catalyze advancements in the efficacy and scope of cancer immunotherapy.

Source: globenewswire.com